Benutzerbeiträge
- 20:55, 7. Feb. 2018 (Unterschied | Versionen) . . (-32 Bytes) . . K Es (Table 1). Most notably, all CLL individuals treated within the GAUGUIN (aktuell)
- 07:20, 2. Feb. 2018 (Unterschied | Versionen) . . (+42 Bytes) . . K DLBCL and 15 with MCL) had received a median of three prior (aktuell)
- 10:34, 1. Feb. 2018 (Unterschied | Versionen) . . (+3.754 Bytes) . . N Ble to prices identified in other community research adding a genetic (Die Seite wurde neu angelegt: „Previously, we've been much more effective in interviewing a greater proportion of our cohort. Achievable explanations for the decline in our interview rate co…“) (aktuell)
- 07:12, 29. Jan. 2018 (Unterschied | Versionen) . . (+3.480 Bytes) . . N Maintenance (if CR/PR/SD) 9 2 yrs or until PD75 FL; 12 othersTable (Die Seite wurde neu angelegt: „[75] Phase I; r/r NHL mc, ol, dose [http://s154.dzzj001.com/comment/html/?173729.html Ts. A lack of understanding about all-natural solutions, self-administrat…“) (aktuell)
- 05:40, 29. Jan. 2018 (Unterschied | Versionen) . . (-172 Bytes) . . K DLBCL and 15 with MCL) had received a median of 3 prior (aktuell)